Please assess the completion status of the following clinical trial:

Trial Title: Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Minor Patient with alveolar proteinosis by double mutation Ala393Thr and SER567LEU of the MARS gene, genetically proven.~* Patient in need of prolonged hospitalization in Necker for treatment of bronchial-alveolar washes in the context of care.~* Patient for which methionine can be administered orally or by enteral probe (Nasogastric or gastrostomy probe)~* Signed Informed consent form by parents / legal guardian~Exclusion Criteria:~* Patient with alveolar proteinosis by other mutations of the MARS gene~* Patient with alveolar proteinosis secondary to another etiology or without identified cause~* Refusal to participate in the study~* High blood pressure requiring drug treatment~* Heart failure~* Known hypersensitivity to one of the substances used or potentially used in the study: methionine, vitamins B6, B12, B9 and C~* Pre-Hypermethioninemia (Methioninemia \> + 2 DS of normal for age) whatever the cause

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Methionine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).